Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

Completed · Phase 1

Conditions studied: Hematologic Malignancies

In brief

The goal of this clinical research study is to find the highest dose of Tezacitabine (FMdC) which can be safely given as a continuous infusion by vein to patients with hematologic malignancies. The general safety and effectiveness of this drug will also be studied.

Key facts

Study ID

NCT00061620

Run by

M.D. Anderson Cancer Center

People needed

19

Starts

2001-09-06

Expected to finish

2004-02-12

Last updated by the study team

2018-11-01

Who can join

Age: 15 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.